NAV

Fosmidomycin

Identification

Generic Name
Fosmidomycin
DrugBank Accession Number
DB02948
Background

Not Available

Type
Small Molecule
Groups
Experimental, Investigational
Structure
3D
Similar Structures
Weight
Average: 183.0997
Monoisotopic: 183.029658947
Chemical Formula
C4H10NO5P
Synonyms
  • Fosmidomycin
  • Fosmidomycina
  • Fosmidomycine
  • Fosmidomycinum

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
TargetActionsOrganism
U1-deoxy-D-xylulose 5-phosphate reductoisomeraseNot AvailableEscherichia coli (strain K12)
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
AcenocoumarolThe risk or severity of bleeding can be increased when Fosmidomycin is combined with Acenocoumarol.
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Fosmidomycin.
DicoumarolThe risk or severity of bleeding can be increased when Fosmidomycin is combined with Dicoumarol.
EstetrolThe therapeutic efficacy of Estetrol can be decreased when used in combination with Fosmidomycin.
FluindioneThe risk or severity of bleeding can be increased when Fosmidomycin is combined with Fluindione.
LactuloseThe therapeutic efficacy of Lactulose can be decreased when used in combination with Fosmidomycin.
PhenindioneThe risk or severity of bleeding can be increased when Fosmidomycin is combined with Phenindione.
PhenprocoumonThe risk or severity of bleeding can be increased when Fosmidomycin is combined with Phenprocoumon.
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Fosmidomycin.
Typhoid vaccineThe therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Fosmidomycin.
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Fosmidomycin sodiumIYI1EW66CX66508-37-0ZZPUYRHMTGOTEU-UHFFFAOYSA-M

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as organic phosphonic acids. These are organic compounds containing phosphonic acid.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Organic phosphonic acids and derivatives
Sub Class
Organic phosphonic acids
Direct Parent
Organic phosphonic acids
Alternative Parents
Hydroxamic acids / Organopnictogen compounds / Organophosphorus compounds / Organonitrogen compounds / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
Substituents
Aliphatic acyclic compound / Carbonyl group / Carboxylic acid derivative / Hydrocarbon derivative / Hydroxamic acid / Organic nitrogen compound / Organic oxide / Organic oxygen compound / Organonitrogen compound / Organooxygen compound
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
phosphonic acids, hydroxamic acid (CHEBI:443725)
Affected organisms
Not Available

Chemical Identifiers

UNII
5829E3D9I9
CAS number
66508-53-0
InChI Key
GJXWDTUCERCKIX-UHFFFAOYSA-N
InChI
InChI=1S/C4H10NO5P/c6-4-5(7)2-1-3-11(8,9)10/h4,7H,1-3H2,(H2,8,9,10)
IUPAC Name
[3-(N-hydroxyformamido)propyl]phosphonic acid
SMILES
ON(CCCP(O)(O)=O)C=O

References

General References
Not Available
PubChem Compound
572
PubChem Substance
46508936
ChemSpider
555
BindingDB
50153713
ChEBI
443725
ChEMBL
CHEMBL203125
ZINC
ZINC000012502867
Therapeutic Targets Database
DAP001384
PDBe Ligand
FOM
Wikipedia
Fosmidomycin
PDB Entries
1onp / 1q0h / 1q0l / 2egh / 2jcv / 2jcx / 3a06 / 3au9 / 3upy / 4aic …
show 6 more

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentPlasmodium Infections1
2CompletedTreatmentPlasmodium Infections2
2Unknown StatusTreatmentOral Treatment of Acute Uncomplicated Plasmodium Falciparum Malaria1
2Unknown StatusTreatmentPlasmodium Infections2
2WithdrawnTreatmentPlasmodium Infections1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility21.9 mg/mLALOGPS
logP-1.1ALOGPS
logP-2.2ChemAxon
logS-0.92ALOGPS
pKa (Strongest Acidic)1.81ChemAxon
pKa (Strongest Basic)-5.6ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area98.07 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity36.83 m3·mol-1ChemAxon
Polarizability15.06 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption-0.9277
Blood Brain Barrier+0.9098
Caco-2 permeable-0.6781
P-glycoprotein substrateNon-substrate0.6815
P-glycoprotein inhibitor INon-inhibitor0.9025
P-glycoprotein inhibitor IINon-inhibitor0.9359
Renal organic cation transporterNon-inhibitor0.9023
CYP450 2C9 substrateNon-substrate0.7726
CYP450 2D6 substrateNon-substrate0.8081
CYP450 3A4 substrateNon-substrate0.5727
CYP450 1A2 substrateNon-inhibitor0.7958
CYP450 2C9 inhibitorNon-inhibitor0.856
CYP450 2D6 inhibitorNon-inhibitor0.9187
CYP450 2C19 inhibitorNon-inhibitor0.8218
CYP450 3A4 inhibitorNon-inhibitor0.6376
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9611
Ames testAMES toxic0.5096
CarcinogenicityNon-carcinogens0.6785
BiodegradationNot ready biodegradable0.7712
Rat acute toxicity2.2352 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9383
hERG inhibition (predictor II)Non-inhibitor0.869
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Details1. 1-deoxy-D-xylulose 5-phosphate reductoisomerase
Kind
Protein
Organism
Escherichia coli (strain K12)
Pharmacological action
Unknown
General Function
Nadph binding
Specific Function
Catalyzes the NADP-dependent rearrangement and reduction of 1-deoxy-D-xylulose-5-phosphate (DXP) to 2-C-methyl-D-erythritol 4-phosphate (MEP).
Gene Name
dxr
Uniprot ID
P45568
Uniprot Name
1-deoxy-D-xylulose 5-phosphate reductoisomerase
Molecular Weight
43387.575 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]

Drug created at June 13, 2005 13:24 / Updated at February 21, 2021 18:51